



Kaleido Biosciences to Participate in the Jefferies Virtual Next Generation IBD Therapeutics Summit

October 12, 2021

LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced that CEO Dan Menichella will present a company overview at the Jefferies Virtual Next Generation IBD Therapeutics Summit at 1:45PM ET on Tuesday, October 19.

The webcast of the presentation will be made available in the Investors & Media section of Kaleido's website at <https://investors.kaleido.com/events-presentations>. An archived replay will be available for 30 days following the event.

About Kaleido Biosciences

Kaleido Biosciences is a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut's existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit <https://kaleido.com/>.

Contacts:

Kaleido Biosciences

William Duke, Jr.
Chief Financial Officer
617-890-5772
william.duke@kaleido.com

Investors and Media

Kotaro Yoshida
Argot Partners
212-600-1902
kaleido@argotpartners.com